

On January 22, Chairman Waxman wrote to FDA Commissioner von Eschenbach requesting documents related to the FDA's draft guidance allowing drug companies to use journal articles to promote potentially dangerous off-label uses of drugs and medical devices without prior FDA review and approval. According to FDA minutes of a meeting, Dan Troy and other drug company representatives urged FDA to issue guidance to protect the companies from "Federal prosecutors pursuing distributors of this information for criminal conduct."

Documents and Links

- [Letter to FDA Commissioner von Eschenbach](#)
- [FDA Response to November 30 Request for Documents](#)
- [Memorandum of April 13 FDA Meeting](#)